Malaysia is a key global supplier, accounting for nearly 50% of the U.S. market for natural-rubber and nitrile gloves — essential healthcare items that must comply with FDA standards. According to the Ministry of Investment, Trade and Industry (MITI), U.S. demand is projected to reach US$4.17 billion by 2030, making uninterrupted access to Malaysian gloves critical for U.S. hospitals and healthcare systems. MARGMA warns that the steep tariff hike could jeopardise patient care, increase costs, and strain supply chains.
Malaysian manufacturers have long shown their commitment to the U.S. market. Notably, Supermax Corporation Berhad has invested US$350 million in a Texas-based production facility, reinforcing the industry’s long-term support for American healthcare.
“MARGMA members stand ready to work with both governments to secure an exemption or at minimum maintain a 10% tariff on rubber gloves,” said Mr Oon Kim Hung, MARGMA President.
“These gloves are not luxury items but essential medical supplies. A 25% tariff will disrupt supply chains, drive up healthcare costs and hinder patient safety.”
The industry has also collaborated with the Malaysian Rubber Board (MRB) and MITI to uphold manufacturing integrity and curb trans-shipment abuse. MARGMA is urging negotiators to seek the sector-specific exemptions that have been granted to other strategic industries, in order to maintain reliable access to Malaysian gloves for U.S. healthcare providers.
MARGMA reaffirmed its commitment to sustainable global supply and called for a balanced resolution that protects public health in both nations.
